The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 15, 2015

Filed:

Apr. 12, 2011
Applicants:

Manuel Baca, Gaithersburg, MD (US);

Thomas Thisted, Gaithersburg, MD (US);

Jeffrey Swers, Gaithersburg, MD (US);

David Tice, Gaithersburg, MD (US);

Inventors:

Manuel Baca, Gaithersburg, MD (US);

Thomas Thisted, Gaithersburg, MD (US);

Jeffrey Swers, Gaithersburg, MD (US);

David Tice, Gaithersburg, MD (US);

Assignee:

MEDIMMUNE, LLC, Gaithersburg, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 19/00 (2006.01); C07K 14/47 (2006.01); C07K 14/78 (2006.01); C07K 16/10 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); C07K 14/00 (2006.01); C07K 14/715 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 19/00 (2013.01); C07K 14/001 (2013.01); C07K 14/78 (2013.01); C07K 16/1027 (2013.01); C07K 16/2878 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/73 (2013.01); C07K 2317/90 (2013.01); C07K 2318/20 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/70 (2013.01); C07K 2319/74 (2013.01);
Abstract

The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increased stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer.


Find Patent Forward Citations

Loading…